TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9579717
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg once daily for 8-10 days
Study: 7900711
Drug: Lorazepam (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (as an adjunct to metoclopramide, dexamethasone, and clemastine)
Study: 24793528
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg conbercept (PRN)
Study: 24793528
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg conbercept (Q1M)
Study: 24793528
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg conbercept (PRN)
Study: 24793528
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg conbercept (Q1M)
Study: 24793528
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg conbercept
Study: 24793528
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg conbercept
Study: 22573504
Drug: Control (occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (occupational therapy)
Study: 17332788
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation alone
Study: 17332788
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation with superimposed exercise
Study: 29778481
Drug: Anti-IL-10 egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-10 egg yolk antibodies (MAB, n = 71)
Study: 29778481
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without anti-IL-10 antibodies (MEP, n = 62)
Study: 29778481
Drug: Anti-IL-10 egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL-10 egg yolk antibodies (MAB)
Study: 21983163
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of 10mg rosuvastatin
Study: 21983163
Drug: Alternate-day dosing
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day dosing of 10mg rosuvastatin
Study: 18445991
Drug: LOS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS group (losartan 25 mg alone)
Study: 18445991
Drug: LOS+BUC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS+BUC group (losartan 25 mg after bucolome 300 mg for 7 days)
Study: 18445991
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (losartan 10 mg/kg for 14 days)
Study: 18445991
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (losartan 10 mg/kg and bucolome 50 mg/kg for 14 days)
Study: 16330675
Drug: Doxorubicin-cisplatin (AP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin-cisplatin (AP) chemotherapy (60 mg/m2 doxorubicin and 50 mg/m2 cisplatin every 3 weeks for seven cycles, followed by one cycle of cisplatin)
Study: 16330675
Drug: Doxorubicin-cisplatin (AP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin-cisplatin (AP) chemotherapy
Study: 14616410
Drug: Voriconazole +
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole + Warfarin
Study: 14616410
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Warfarin
Study: 8928327
Drug: Estimation according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estimation according to E.G. Lowrei
Study: 8928327
Drug: Estimation according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estimation according to L. Garred et. al.
Study: 6144829
Drug: Intradermal HDCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal HDCV (0.1 ml doses)
Study: 6144829
Drug: Intramuscular HDCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular HDCV (1.0 ml doses)
Study: 27216112
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioural Therapy (dCBT) delivered via web and/or mobile channels
Study: 27216112
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioural Therapy (dCBT)
Study: 25244260
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (antiretroviral therapy and counseling only)
Study: 23013802
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg intravenously every 6 hours for 7 days) and Clonidine (0.1 mg per tube every 12 hours for 7 days)
Study: 20006165
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 10 mg
Study: 18835099
Drug: Acidic phosphate
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acidic phosphate buffer (pH 5.2) at 40 ml/h
Study: 18835099
Drug: Acidic phosphate
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acidic phosphate buffer (pH 5.2) at 20 ml/h
Study: 18835099
Drug: Normal phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal phosphate buffer (pH 7.3) at 40 ml/h
Study: 18835099
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline at 40 ml/h
Study: 16438016
Drug: Cisatracurium Bolus
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium Bolus (0.15 mg/kg) - Group A
Study: 16438016
Drug: Cisatracurium Infusion
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium Infusion (0.18 mg/kg/h) - Group B
Study: 12885803
Drug: Rhenium-188 hydroxyethylidenediphosphonate
Normalized name: RHENIUM
DrugBank: Rhenium re-186 (DB19266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - two injections (group B)
Study: 12885803
Drug: Rhenium-188 hydroxyethylidenediphosphonate
Normalized name: RHENIUM
DrugBank: Rhenium re-186 (DB19266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - single injection (group A)
Study: 10475142
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of distigmine (14C-distigmine-bromide)
Study: 10475142
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 14C-distigmine-bromide
Study: 1912107
Drug: Biperiden 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden 8 mg
Study: 29465346
Drug: Tocilizumab 4
Normalized name: tocilizumab 400 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 4 mg/kg with methotrexate
Study: 29465346
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg with methotrexate
Study: 19800061
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (0.25 mg/d on days 1, 2, and 3 of the menstrual cycle)
Study: 19800061
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GnRH antagonist supplementation)
Study: 18341675
Drug: Phosphodiesterase 4
Normalized name: Phosphodiesterase 4 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase 4 inhibitors
Study: 16841667
Drug: Gegen Qinlian
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gegen Qinlian Decoction (GQD) combined with insulin treatment
Study: 16841667
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (insulin treatment alone)
Study: 9121664
Drug: 14G intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14G intravenous catheter
Study: 9121664
Drug: 16G intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16G intravenous catheter
Study: 7688829
Drug: Flutamide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (375 mg p.o. daily)
Study: 7688829
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) (100 mg p.o. daily)
Study: 2953226
Drug: Intracoronary nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicardipine (0.2 mg)
Study: 30463608
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual care with financial incentives (up to $550) for participating in the New York Smoker's Quitline, using nicotine replacement therapy, and achieving biochemically confirmed smoking cessation at 2 months and 6 months.
Study: 26306520
Drug: Pegfilgrastim administration
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administration 24 hours after chemotherapy (cohort A)
Study: 26306520
Drug: Pegfilgrastim administration
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administration 72 hours after chemotherapy (cohort B)
Study: 26306520
Drug: Pegfilgrastim administration
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administration 96 hours after chemotherapy (cohort C)
Study: 24865694
Drug: Low-dose CTPA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CTPA (80 kVp, 75 ml CM)
Study: 24865694
Drug: Normal-dose CTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose CTPA (100 kVp, 100 ml CM)
Study: 2039963
Drug: Telebrix 38
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telebrix 38 (2% solution in water)
Study: 2039963
Drug: Gastrografin (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (2% solution in water)
Study: 7215768
Drug: Intravenous sulprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sulprostone
Study: 7215768
Drug: Extraamniotic injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraamniotic injections
Study: 7215768
Drug: Extra-amniotic injections
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic injections following intramuscular injection for priming
Study: 7215768
Drug: Priming administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming administration
Study: 28939746
Drug: Radotinib 300
Normalized name: Radotinib
DrugBank: Radotinib (DB12323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radotinib 300 mg
Study: 28939746
Drug: Radotinib 400
Normalized name: Radotinib
DrugBank: Radotinib (DB12323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radotinib 400 mg
Study: 31592954
Drug: Basic LV
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic LV services (LV devices dispensed without therapy)
Study: 28329346
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 8 mg/kg
Study: 28329346
Drug: Ivermectin (IVM)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (IVM) 200 µg/kg
Study: 26083950
Drug: DC-TC (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-TC (in patients with no evidence of disease at treatment start)
Study: 26083950
Drug: TC (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (in patients with no evidence of disease at treatment start)
Study: 17623225
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (15 ml/day, 8.1 g ALA)
Study: 17623225
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (15 ml/day, 11.2 g LA)
Study: 15708217
Drug: Concurrent verbal
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent verbal interference task during encoding
Study: 15708217
Drug: Concurrent visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent visual interference task during encoding
Study: 10546421
Drug: Ammonium lactate
Normalized name: Ammonium Lactate
DrugBank: Ammonium lactate (DB06768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ammonium lactate 12% lotion
Study: 10546421
Drug: Liposome-based moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome-based moisturizing lotion
Study: 7051452
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg chloroquine base per kg body-weight (single dose)
Study: 7051452
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg chloroquine base per kg body-weight (given over three days)
Study: 25378059
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of subcutaneous immunotherapy (IT3)
Study: 25378059
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of subcutaneous immunotherapy (IT5)
Study: 24988825
Drug: Gabapentin (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (started at 300 mg daily, increased to a maximum of 1800 mg)
Study: 24988825
Drug: Naproxen (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (started at 250 mg daily, increased to a maximum of 1500 mg)
Study: 19487623
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/5 mL) for 12 weeks, mean maximum dosage 16.5 mg/d (maximum 20 mg/d)
Study: 19487623
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg/5 mL) for 12 weeks
Study: 19558735
Drug: Optimal PEEP
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal PEEP plus sigh breaths (twice the baseline tidal volume, plateau pressure < 40 cm H(2)O) every 25 breaths
Study: 14714839
Drug: Implant-supported overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported overdentures
Study: 8186061
Drug: Litoxetine 10
Normalized name: Litoxetine
DrugBank: Litoxetine (DB15038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litoxetine 10 mg
Study: 8186061
Drug: Litoxetine 25
Normalized name: Litoxetine
DrugBank: Litoxetine (DB15038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litoxetine 25 mg
Study: 31219734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statin, dual antiplatelet therapy, and beta-blockers prescribed to 79.6% of patients upon discharge.
Study: 31219734
Drug: Renin-angiotensin-aldosterone system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin-aldosterone system inhibitor prescribed to 67.3% of patients with LVEF ≤40%.
Study: 31219734
Drug: Beta-blocker prescribed
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker prescribed to 91.8% of patients with LVEF ≤40%.
Study: 31219734
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment with statins in patients with prior history of CAD.
Study: 31219734
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment with antiplatelets in patients with prior history of CAD.
Study: 31219734
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment with beta-blockers in patients with prior history of CAD.
Study: 31219734
Drug: Optimal LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal LDL-C of <70 mg/dl at admission in CAD patients.
Study: 26920640
Drug: Humalog® KwikPen™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humalog® KwikPen™ 200 units/mL (IL 200 pen)
Study: 26920640
Drug: Humalog KwikPen
Normalized name: HumaLOG KwikPen
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Humalog KwikPen 100 units/mL (IL 100 pen)
Study: 22705939
Drug: Mindful Movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Movement Program (MMP) - 12 weekly sessions
Study: 15988706
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily for 12 weeks
Study: 12699298
Drug: Calcium enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium enhancement of estrogen's effects, with a recommended intake of 30 to 40 mmol Ca/d and sufficient vitamin D (approximately 25 microg vitamin D/d) to maintain serum 25(OH)D levels above 80 nmol/L.
Study: 12699298
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation in the presence of bone active agents.
Study: 12699298
Drug: Newer anabolic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer anabolic agents requiring higher levels of calcium repletion.
Study: 10480774
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by 600 mg alpha-lipoic acid three times a day orally for 6 months (A-A)
Study: 10480774
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (A-P)
Study: 10480774
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (P-P)
Study: 7815337
Drug: Cocaine HCl
Normalized name: cocaine HCl
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine HCl (80 mg/70 kg p.o.)
Study: 7815337
Drug: Cocaine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (20, 40, 80 and 120 mg/70 kg, oral and intranasal)
Study: 7815337
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 and 0.50 mg/70 kg p.o.)
Study: 7815337
Drug: Cocaine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (oral and intranasal)
Study: 7815337
Drug: Cocaine (training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (training dose)
Study: 6980657
Drug: midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.3 mg kg‐1
Study: 6980657
Drug: thiopentone 3
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thiopentone 3 mg kg‐1
Study: 31869428
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg s.c. for 3 days
Study: 31869428
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg p.o. for 3 days
Study: 31869428
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg for 10 days
Study: 26869679
Drug: Midodrine (MH)
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine (MH) 10 mg
Study: 26869679
Drug: L-NAME 1
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 1 mg/kg
Study: 30003563
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous hydrocortisone infusion (CSHI)
Study: 24517155
Drug: Oral hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrocortisone (OHC)
Study: 22356132
Drug: linagliptin +
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin + high-dose metformin
Study: 22356132
Drug: linagliptin +
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin + low-dose metformin
Study: 22356132
Drug: high-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose metformin
Study: 22356132
Drug: low-dose metformin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose metformin
Study: 22356132
Drug: open-label linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: open-label linagliptin + high-dose metformin
Study: 22356132
Drug: linagliptin +
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin + metformin
Study: 19910547
Drug: Clinical physical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical physical therapy (PT)
Study: 17559146
Drug: IROX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IROX (oxaliplatin 85 mg/m² and irinotecan 200 mg/m² every 3 weeks)
Study: 11740322
Drug: Clarithromycin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (7.5 mg/kg/dose twice a day for 7 days)
Study: 11740322
Drug: Erythromycin (13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (13.3 mg/kg/dose three times a day for 14 days)
Study: 7995001
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole
Study: 2646839
Drug: lotrolan (0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: lotrolan (0.27 osmol/kg, 280 mg J/ml)
Study: 2646839
Drug: lopromide (0.77
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopromide (0.77 osmol/kg, 370 mg J/ml)
Study: 2646839
Drug: Amidotrizoate (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amidotrizoate (2.1 osmol/kg, 370 mg J/ml)
Study: 28662049
Drug: SD+AMX+MET (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD+AMX+MET (both 500mg x 3 times daily TID) for 3 days (group B)